Latest update:
Wednesday, May 18, 2016 - 12:42
18 January 2016
On 01.15.2016, the members of the European Generic and Biosimilar Medicines Association (EGA), whose member is also the Bulgarian Generic Pharmaceutical Association (BGPharmA) adopted unanimously the disclosure rules. These rules will constitute an important part of the Code of Ethics of EGA (EGA's Code of Conduct), which was adopted a year ago. The rules provide a framework for disclosing the support to patient organizations and health professionals, such as conducting meetings and educational seminars, as well as assistance for health organizations. The EGA members will have one year at their disposal, to put into practice the disclosure requirements, as they will start applying them a from January 2017, with the purpose of public disclosure in 2018. “We are proud that the industry of generic, biosimilar and value-added medicines has taken another important step and further refined its existing Code of Ethics. Disclosure shall allow the industry, healthcare professionals and patient organizations to promote together the shared values of transparency, integrity, responsibility and collaboration”, stated Jacek Glinka, the EGA President. The European Generic and Biosimilar Medicines Association (EGA) represents the European sectors of generic, biosimilar and value-added medicines, which provide high quality medicines at competitive prices to millions of European patients. The companies represented by EGA provide over 160,000 skilled jobs throughout Europe. Without genericsmedicines, the payers in Europe would have to pay 100 billion euro more in 2014. The share of genericmedicines is 56% of all administeredmedicines, but only 22% of the pharmaceutical expenditure in Europe. The vision of the European producers of generic and biosimilar medicines is to provide sustainable access to high-quality medicines for all European patients based on five important pillars: patients, quality, value, sustainability and partnership.